{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymoblastoma&page=18",
    "query": {
      "condition": "Ependymoblastoma",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 776,
    "total_pages": 78,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymoblastoma&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymoblastoma&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:33:33.695Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06068075",
      "title": "Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Ewing Sarcoma of Bone",
        "Ewing Sarcoma of Soft Tissue",
        "Peripheral Primitive Neuroectodermal Tumor",
        "Peripheral Primitive Neuroectodermal Tumor of Bone",
        "Peripheral Primitive Neuroectodermal Tumor of Soft Tissue",
        "High-grade Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "FoundationOne Liquid CDx",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 340,
      "start_date": "2018-05-08",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06068075"
    },
    {
      "nct_id": "NCT02162732",
      "title": "Molecular-Guided Therapy for Childhood Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuroblastoma",
        "Medulloblastoma",
        "Glioma",
        "Ependymoma",
        "Choroid Plexus Neoplasms",
        "Craniopharyngioma",
        "Dysembryoplastic Neuroepithelial Tumor",
        "Meningioma",
        "Primitive Neuroectodermal Tumors (PNETs)",
        "Germ Cell Tumors",
        "Rhabdomyosarcoma",
        "Non-rhabdomyosarcoma",
        "Ewings Sarcoma",
        "Osteosarcoma",
        "Wilms Tumor",
        "Renal Cell Carcinoma",
        "Malignant Rhabdoid Tumor",
        "Clear Cell Sarcoma",
        "Liver Tumors"
      ],
      "interventions": [
        {
          "name": "Guided Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Giselle Sholler",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "13 Months to 21 Years"
      },
      "enrollment_count": 186,
      "start_date": "2014-07-08",
      "completion_date": "2024-01-18",
      "has_results": true,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 18,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02162732"
    },
    {
      "nct_id": "NCT04661384",
      "title": "Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ependymoma",
        "Glioblastoma",
        "Medulloblastoma",
        "Recurrent Metastatic Malignant Neoplasm in the Leptomeninges"
      ],
      "interventions": [
        {
          "name": "IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-03-05",
      "completion_date": "2027-01-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04661384"
    },
    {
      "nct_id": "NCT03361033",
      "title": "Components of Social Functioning in Survivors of Pediatric Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Tumor, Pediatric",
        "Medulloblastoma, Pediatric"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "8 Years to 12 Years"
      },
      "enrollment_count": 80,
      "start_date": "2018-01-30",
      "completion_date": "2022-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03361033"
    },
    {
      "nct_id": "NCT02110563",
      "title": "Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Multiple Myeloma",
        "Non-Hodgkins Lymphoma",
        "Pancreatic Neuroendocrine Tumors",
        "PNET",
        "NHL"
      ],
      "interventions": [
        {
          "name": "DCR-MYC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-04",
      "completion_date": "2016-11-03",
      "has_results": false,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02110563"
    },
    {
      "nct_id": "NCT01619865",
      "title": "Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Carcinoid Tumors",
        "Neuroblastoma",
        "Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "68Ga-DOTATOC PET/CT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sue O'Dorisio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2012-02-21",
      "completion_date": "2017-08-27",
      "has_results": true,
      "last_update_posted_date": "2021-07-27",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619865"
    },
    {
      "nct_id": "NCT00002730",
      "title": "Chemotherapy in Treating Children With Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "buthionine sulfoximine",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "0 Years to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1996-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002730"
    },
    {
      "nct_id": "NCT01713439",
      "title": "Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Injection of allogeneic neuroblastoma cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 32,
      "start_date": "1997-12",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2023-07-12",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01713439"
    },
    {
      "nct_id": "NCT04211675",
      "title": "NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Neuroblastoma",
        "Refractory Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Natural Killer Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Dinutuximab",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 31,
      "start_date": "2022-09-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04211675"
    },
    {
      "nct_id": "NCT00822458",
      "title": "GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Childhood Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "vismodegib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 34,
      "start_date": "2009-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-04-02",
      "last_synced_at": "2026-11-19T07:33:33.695Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822458"
    }
  ]
}